Table 3.
Disease Severity and Treatment Outcomes
| Treatment Outcomes | Frequency | Percent |
|---|---|---|
| Disease severity (n=467) | ||
| Mild | 27 | 5.8 |
| Moderate | 34 | 7.1 |
| Severe | 91 | 19.1 |
| Critical | 315 | 66.0 |
| Treatment Modalities (n=477) | ||
| Dexamethasone | 396 | 83.0 |
| Enoxaparin | 361 | 75.7 |
| Oxygen | 348 | 73.0 |
| Non-rebreather mask | 272 | 80.0 |
| Nasal prong | 92 | 30.0 |
| High-flow nasal canula | 19 | 10.0 |
| CPAP | 3 | 1.0 |
| Ceftriaxone | 333 | 69.8 |
| Zinc | 282 | 59.1 |
| Azithromycin | 162 | 34.0 |
| Nebulization | 95 | 19.9 |
| Antihypertensives | 63 | 13.2 |
| N-acetyl cysteine | 42 | 8.8 |
| Piperacillin/tazobactam | 27 | 5.7 |
| Vitamin C | 19 | 4.0 |
| Amoxycillin/clavulanic acid | 6 | 1.3 |
| Ivermectin | 2 | 0.4 |
| Remdesivir | 1 | 0.2 |